Madrigal Pharmaceuticals Inc (MDGL)
217.58
-18.52
(-7.84%)
USD |
NASDAQ |
May 07, 16:00
215.22
-2.36
(-1.08%)
After-Hours: 17:37
Madrigal Pharmaceuticals Accounts Payable (Quarterly): 28.04M for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 28.04M |
September 30, 2023 | 16.54M |
June 30, 2023 | 17.53M |
March 31, 2023 | 12.13M |
December 31, 2022 | 23.83M |
September 30, 2022 | 18.56M |
June 30, 2022 | 11.29M |
March 31, 2022 | 22.78M |
December 31, 2021 | 21.38M |
September 30, 2021 | 10.42M |
June 30, 2021 | 1.067M |
March 31, 2021 | 4.396M |
December 31, 2020 | 1.017M |
September 30, 2020 | 6.277M |
June 30, 2020 | 5.004M |
March 31, 2020 | 1.115M |
December 31, 2019 | 1.178M |
September 30, 2019 | 0.773M |
June 30, 2019 | 0.446M |
March 31, 2019 | 4.376M |
December 31, 2018 | 2.487M |
September 30, 2018 | 1.031M |
June 30, 2018 | 0.588M |
March 31, 2018 | 1.42M |
December 31, 2017 | 1.929M |
Date | Value |
---|---|
September 30, 2017 | 1.40M |
June 30, 2017 | 1.285M |
March 31, 2017 | 2.78M |
December 31, 2016 | 0.762M |
September 30, 2016 | 1.160M |
June 30, 2016 | 0.68M |
March 31, 2016 | 0.744M |
December 31, 2015 | 0.1023M |
September 30, 2015 | 1.424M |
June 30, 2015 | 3.018M |
March 31, 2015 | 3.738M |
December 31, 2014 | 3.139M |
September 30, 2014 | 4.442M |
June 30, 2014 | 5.226M |
March 31, 2014 | 5.81M |
December 31, 2013 | 6.589M |
September 30, 2013 | 5.693M |
June 30, 2013 | 5.222M |
March 31, 2013 | 5.719M |
December 31, 2012 | 5.661M |
September 30, 2012 | 3.69M |
June 30, 2012 | 3.468M |
March 31, 2012 | 3.04M |
December 31, 2011 | 3.467M |
September 30, 2011 | 2.921M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
0.446M
Minimum
Jun 2019
28.04M
Maximum
Dec 2023
10.73M
Average
10.42M
Median
Sep 2021
Accounts Payable (Quarterly) Benchmarks
Eli Lilly and Co | 2.474B |
Viking Therapeutics Inc | 5.225M |
Akero Therapeutics Inc | 7.038M |
89bio Inc | 8.585M |
Geron Corp | 9.992M |